Page last updated: 2024-10-23

baclofen and Alcohol Abuse

baclofen has been researched along with Alcohol Abuse in 217 studies

Research Excerpts

ExcerptRelevanceReference
"Baclofen did not lead to a differential change in cognitive biases compared with placebo, and trait anxiety levels did not moderate this."9.27Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein? ( Beraha, EM; Krediet, E; Salemink, E; Wiers, RW, 2018)
" A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P < 0."9.19Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. ( Addolorato, G; Baillie, A; Haber, PS; Leggio, L; Leung, S; Morley, KC, 2014)
"Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis."9.12Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. ( Abenavoli, L; Addolorato, G; Caputo, F; Cardone, S; D'Angelo, C; Ferrulli, A; Gasbarrini, G; Haber, PS; Leggio, L; Mirijello, A; Vonghia, L; Zambon, A, 2007)
"90 patients with alcoholism stage II suffering from secondary affective disorders (anxiety, depression) were divided into 4 groups: treated with GABA-B-receptor ligand baclofen (group 1), with sibazon (group 2), amitriptylin (group 3), placebo (group 4)."9.07[The use of baclofen for treating affective disorders in alcoholism]. ( Borodkin, IuS; Burakov, AM; Grinenko, AIa; Ivanov, VB; Karandashova, GF; Krupitskiĭ, EM; Lapin, IP, 1994)
"Baclofen, a very potent agonist of the GABA system, has anti-craving properties that can provide to this old drug, usually prescribed against spasticity, a new interest in the treatment of alcoholism."8.87[Baclofen: the new miracle cure for alcoholism?]. ( Gache, P, 2011)
"Baclofen self-poisoning by alcohol-dependent patients is a serious concern for the French health authorities."7.85Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008-2013. ( Cardona, F; de Haro, L; Franchitto, N; Pelissier, F; Picot, C; Puskarczyk, E; Sapori, JM; Tournoud, C, 2017)
"The first case concerns a 60-year-old man who reported tinnitus when he reached a 180 mg/d dose of baclofen after 3 months of treatment."7.80Severe tinnitus induced by off-label baclofen. ( Auffret, M; Bordet, R; Cottencin, O; Deheul, S; Gautier, S; Hennaux, C; Loche, V; Rolland, B, 2014)
"Baclofen safety was evaluated by adverse reaction occurrence during treatment."7.01Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases. ( Chang, C; Cheng, J; Duan, F; Li, J; Liu, C; Song, S; Yang, S; Zhai, H, 2023)
"Oral baclofen was given at dosages of 0 (placebo) or 30 mg/day over 12 weeks with concomitant manual-guided counseling."6.84The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. ( Dieperink, E; Fuller, B; Hauser, P; Ho, SB; Kern, S; Thuras, P, 2017)
"A 23-year-old man with a history of alcohol dependence was admitted to our hospital after self-intoxication with 2700 mg baclofen and 330 mg mirtazapine."5.43[Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms]. ( de Witte, LD; Dekker, D; Kaasjager, K; Kromkamp, M; Veraart, J; Vinkers, CH, 2016)
" HDB induces frequent neuropsychiatric adverse events (AEs)."5.42Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. ( Auffret, M; Bordet, R; Cottencin, O; Danel, T; Deheul, S; Gautier, S; Langlois, C; Rolland, B; Valin, T, 2015)
"Data from a randomised controlled trial (RCT) (N = 104), in which AUD patients received placebo or baclofen (30 mg/day or 75 mg/day) for 12 weeks, were analysed to determine predictive effects of the following four clinical characteristics: alcoholic liver disease (ALD), baseline alcohol consumption, craving and anxiety."5.30Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. ( Baillie, A; Haber, PS; Morley, KC; Rombouts, SA, 2019)
"Baclofen did not lead to a differential change in cognitive biases compared with placebo, and trait anxiety levels did not moderate this."5.27Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein? ( Beraha, EM; Krediet, E; Salemink, E; Wiers, RW, 2018)
" Baclofen has been shown to promote abstinence, to reduce craving, and to reduce anxiety in alcohol-dependent individuals, and it promises to be a useful agent, although clinical data are limited at present."5.24Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. ( Arora, S; Elwadhi, D; Gupta, M; Rastogi, R; Verma, P, 2017)
" A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P < 0."5.19Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. ( Addolorato, G; Baillie, A; Haber, PS; Leggio, L; Leung, S; Morley, KC, 2014)
"Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis."5.12Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. ( Abenavoli, L; Addolorato, G; Caputo, F; Cardone, S; D'Angelo, C; Ferrulli, A; Gasbarrini, G; Haber, PS; Leggio, L; Mirijello, A; Vonghia, L; Zambon, A, 2007)
"90 patients with alcoholism stage II suffering from secondary affective disorders (anxiety, depression) were divided into 4 groups: treated with GABA-B-receptor ligand baclofen (group 1), with sibazon (group 2), amitriptylin (group 3), placebo (group 4)."5.07[The use of baclofen for treating affective disorders in alcoholism]. ( Borodkin, IuS; Burakov, AM; Grinenko, AIa; Ivanov, VB; Karandashova, GF; Krupitskiĭ, EM; Lapin, IP, 1994)
" Baclofen shows potential for rapidly reducing symptoms of severe AWS in people with alcoholism."5.01Baclofen for alcohol withdrawal. ( Liu, J; Wang, LN, 2019)
"Baclofen, a very potent agonist of the GABA system, has anti-craving properties that can provide to this old drug, usually prescribed against spasticity, a new interest in the treatment of alcoholism."4.87[Baclofen: the new miracle cure for alcoholism?]. ( Gache, P, 2011)
" Different lines of evidence indicate that direct agonists, including baclofen, effectively suppress acquisition and maintenance of alcohol drinking behavior, relapse-like drinking, and alcohol's reinforcing, rewarding, stimulating, and motivational properties in rats and mice."4.85Role of the GABA(B) receptor in alcohol-seeking and drinking behavior. ( Colombo, G; Maccioni, P, 2009)
"Baclofen self-poisoning by alcohol-dependent patients is a serious concern for the French health authorities."3.85Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008-2013. ( Cardona, F; de Haro, L; Franchitto, N; Pelissier, F; Picot, C; Puskarczyk, E; Sapori, JM; Tournoud, C, 2017)
"The first case concerns a 60-year-old man who reported tinnitus when he reached a 180 mg/d dose of baclofen after 3 months of treatment."3.80Severe tinnitus induced by off-label baclofen. ( Auffret, M; Bordet, R; Cottencin, O; Deheul, S; Gautier, S; Hennaux, C; Loche, V; Rolland, B, 2014)
" As baclofen suppressed ethanol self-administration and showed evidence of increased potency in dependent animals, the present experiment suggests that the GABA(B) receptor could be a potential pharmacotherapeutic target for the treatment of chronic alcoholism."3.74The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. ( Koob, GF; Walker, BM, 2007)
"These results are in close agreement with those of a preliminary clinical study and suggest that baclofen may constitute a novel therapeutic agent for alcoholism."3.70Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence. ( Addolorato, G; Agabio, R; Carai, MA; Colombo, G; Gessa, GL; Lobina, C; Pani, M; Reali, R, 2000)
"Baclofen has been shown to reduce alcohol consumption in some individuals with alcohol use disorder."3.30Hypothalamic-pituitary-adrenocortical response in alcohol-dependent patients during baclofen treatment and association with clinical outcome: Preliminary results. ( Arunogiri, S; Baillie, A; Haber, PS; Hurzeler, T; Logge, W; Morley, K; Towers, E, 2023)
"Baclofen was well tolerated and may be considered for the management of alcohol withdrawal syndrome, especially useful in situations where benzodiazepines should be withheld, such as patients with liver impairment."3.30Baclofen during alcohol detoxification reduces the need for additional diazepam: a randomized placebo-controlled trial. ( Crunelle, CL; Jegham, S; Matthys, F; Vanderbruggen, N, 2023)
"Twenty-eight recently detoxified patients (13 receiving baclofen (BAC), 15 receiving placebo (PLA)) were investigated within a longitudinal, double-blind, and randomized pharmaco-fMRI design with an individually adjusted daily dosage of 30-270 mg."3.30Effects of baclofen on insular gain anticipation in alcohol-dependent patients - a randomized, placebo-controlled, pharmaco-fMRI pilot trial. ( Beck, A; Charlet, K; Geisel, O; Genauck, A; Gleich, T; Heinz, A; Lorenz, RC; Müller, CA; Pelz, P; Wackerhagen, C; Wüstenberg, T, 2023)
"Baclofen safety was evaluated by adverse reaction occurrence during treatment."3.01Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases. ( Chang, C; Cheng, J; Duan, F; Li, J; Liu, C; Song, S; Yang, S; Zhai, H, 2023)
"Baclofen daily dose was 30 mg to 300 mg: 10 RCTs used low doses (30 mg or less); eight RCTs medium doses (above 30 and 100 mg or less) and four RCTs high doses (above 100 mg)."3.01Baclofen for alcohol use disorder. ( Agabio, R; Minozzi, S; Rösner, S; Saulle, R, 2023)
"Both baclofen-treated groups reported fewer post-scan % HDD when compared to the placebo-treated group, but no subjective craving group differences were found."3.01Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. ( Baillie, AJ; Haber, PS; Logge, WB; Morley, KC; Morris, RW, 2021)
"Baclofen is a selective GABA-B receptor agonist which has been investigated as a potential treatment for alcohol use disorder."3.01A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. ( Akhlaghi, F; Deschaine, SL; Farinelli, LA; Farokhnia, M; Lee, MR; Leggio, L; Sadighi, A, 2021)
"Treatment with baclofen further led to a decrease in alcohol cue-modulated functional connectivity between left VTA and left anterior cingulate cortex (ACC) as well as left medial prefrontal cortex (MPFC)."2.87Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study. ( Beck, A; Charlet, K; Geisel, O; Heinz, A; Lorenz, RC; Müller, CA; Pelz, P; Wüstenberg, T, 2018)
"Oral baclofen was given at dosages of 0 (placebo) or 30 mg/day over 12 weeks with concomitant manual-guided counseling."2.84The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. ( Dieperink, E; Fuller, B; Hauser, P; Ho, SB; Kern, S; Thuras, P, 2017)
"Baclofen was assessed versus placebo for maintenance of abstinence and reduction in alcohol consumption in alcohol-dependent patients."2.84A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study. ( Aubin, HJ; Dano, C; Dematteis, M; Detilleux, M; Paille, F; Reynaud, M; Trinquet, F; Trojak, B; Zakine, B, 2017)
"Baclofen has been suggested as a potential pharmacotherapy for alcohol use disorder, but the clinical data are conflicting."2.84Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. ( Amodio, JP; Bollinger, JW; Farinelli, LA; Farokhnia, M; Lee, MR; Leggio, L; Lionetti, TA; Schwandt, ML; Sewell, L; Spero, DE, 2017)
"The National institute on Alcohol Abuse and Alcoholism (NIAAA) considers alcohol abuse to be more than 14 units of alcohol a week for men and 7 units for women."2.82Baclofen to prevent agitation in alcohol-addicted patients in the ICU: study protocol for a randomised controlled trial. ( Asehnoune, K; Feuillet, F; Mahe, PJ; Sebille, V; Vourc'h, M, 2016)
"Previous randomised placebo-controlled trials with low-to-medium doses of baclofen (30-60mg) showed inconsistent results, but case studies suggested a dose-response effect and positive outcomes in patients on high doses of baclofen (up to 270mg)."2.82Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. ( Bakker, A; Beraha, EM; Bodewits, P; de Jong, D; Defourny, H; Geest, DV; Goudriaan, AE; Salemink, E; Schiphof, T; Smits, N; van den Brink, W; van Tricht, M; Wiers, RW; Zwart, JW, 2016)
"Harmful alcohol use and alcohol use disorders (AUD) result in major health and community burden worldwide, yet treatment options are limited."2.82GABA ( Haber, PS; Logge, WB; Morley, KC, 2022)
"Depression was assessed with Montgomery-Ashberg scale."2.80[Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence]. ( Alexeeva, YV; Berntsev, VA; Chekhlaty, EI; Kiselev, AS; Krupitsky, EM; Neznanov, NG; Popov, YV; Rybakova, KV; Zubova, EY, 2015)
"Effective treatments for alcohol use disorders in those with significant liver disease are critically lacking."2.78The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. ( Baillie, A; Haber, PS; Leung, S; Morley, KC, 2013)
"Baclofen was associated with a significant reduction in state anxiety (F(1,73)= 5."2.75Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. ( Flannery, BA; Gallop, R; Garbutt, JC; Kalka-Juhl, L; Kampov-Polevoy, AB, 2010)
"Baclofen was reasonably tolerated."2.71Baclofen for alcohol dependence: a preliminary open-label study. ( Cody, MW; Crosby, K; Flannery, BA; Garbutt, JC; Grace, K; Morreale, M; Osborne, M; Renn, W; Trivette, A, 2004)
" With the background that individualized, rather than fixed, high dosing with baclofen could be critical for success, a large (n = 320), industry-independent, 62-center French RCT (the Bacloville trial) examined whether individually uptitrated, high-dose baclofen could reduce alcohol consumption in heavy drinkers across a year of treatment."2.66Individualized, High-Dose Baclofen for Reduction in Alcohol Intake in Persons With High Levels of Consumption. ( Andrade, C, 2020)
"Baclofen was superior to placebo with significant increases in TTL (8 RCTs, 852 patients; SMD=0."2.58Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. ( Beraha, EM; Morley, K; Pierce, M; Sutterland, A; van den Brink, W, 2018)
"Participants had a diagnosis of alcohol dependence according the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV or the International Classification of Diseases (ICD)-10 criteria who were currently drinking."2.58Baclofen for alcohol use disorder. ( Minozzi, S; Rösner, S; Saulle, R, 2018)
" For some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function."2.58Alcohol addiction - the safety of available approved treatment options. ( Addolorato, G; Antonelli, M; Ferrulli, A; Gasbarrini, A; Mirijello, A; Mosoni, C; Rando, MM; Sestito, L; Tarli, C; Vassallo, GA, 2018)
"Baclofen is a γ-aminobutyric acid B (GABA-B) agonist which is used increasingly as an off-label treatment."2.58Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. ( Jones, A; Rose, AK, 2018)
"Baclofen is a promising therapeutic in this area."2.55Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies. ( Owens, L; Pirmohamed, M; Richardson, P; Thompson, A, 2017)
"The development of alcohol dependence is associated with significant morbidity and mortality."2.55Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. ( Goh, ET; Morgan, MY, 2017)
" However, HDB has been associated with numerous reports of adverse events (AEs)."2.53Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment. ( Auffret, M; Franchitto, N; Rolland, B, 2016)
"Alcohol use disorders are common, but only a small minority of patients receive adequate treatment."2.52Recent Developments in Pharmacotherapy of Alcoholism. ( Lieb, M; Soyka, M, 2015)
"Baclofen has been tested for its capacity to reduce craving for alcohol."2.49Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013. ( , 2013)
" Questions still remain about optimal dosing and duration."2.48Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence. ( Gagliardi, JP; Muzyk, AJ; Rivelli, SK, 2012)
" Thus, baclofen should benefit from further studies of its biobehavioral mechanisms, dose-response effect, and indications in various alcoholic patient profiles."2.48Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates. ( Aubin, HJ; Benyamina, A; Blecha, L; Gorsane, MA; Hache, G; Kebir, O; Reynaud, M, 2012)
" The outcomes considered were alcohol withdrawal seizures, adverse events and dropouts."2.47Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. ( Amato, L; Davoli, M; Minozzi, S, 2011)
" Notably, baclofen has shown a safe profile when administered to alcoholics, including those with liver cirrhosis."2.46Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. ( Addolorato, G; Leggio, L, 2010)
"Acamprosate has demonstrated efficacy for treating alcohol dependence in European trials, but with a small effect size."2.44Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. ( Johnson, BA, 2008)
"Treatment with baclofen also suppressed the number of daily drinks and decreased the obsessive and compulsive components of alcohol craving."2.42Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. ( Addolorato, G; Agabio, R; Carai, MA; Colombo, G; Gessa, GL; Pibiri, F; Serra, S; Vacca, G, 2004)
" The usual side effects such as drowsiness were frequent (22%) but no serious adverse events (AEs) or overt encephalopathy related to baclofen was reported."1.91Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study. ( Alqallaf, S; Barrault, C; Behar, V; Bourcier, V; Cadranel, JF; Costentin, C; Hagege, H; Jung, C; Labarriere, D; Lamote-Chaouche, I; Laugier, J; Le Gruyer, A; Lison, H; Ripault, MP; Thevenot, T, 2023)
"Baclofen has been trialled for AUD in cirrhosis and appears to be effective."1.72Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice. ( Cheng, A; Habtemariam, Z; Kelleher, C; Lewis, H; Lovendoski, J; Strathie, K; Tyson, LD, 2022)
"R(+)-Baclofen was more effective than RS(±)-Baclofen in reducing ethanol intake and seeking during acute withdrawal and during relapse after abstinence."1.62Is R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side. ( Bloch, V; Echeverry-Alzate, V; Jeanblanc, J; Labat, L; Naassila, M; Sauton, P; Soichot, M; Vorspan, F, 2021)
"Medical management of alcohol use disorders."1.51[Medical management of alcohol use disorders]. ( Paille, F, 2019)
"Baclofen exposure was significantly associated with hospitalisation (hazard ratio [HR] = 1."1.48Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. ( Chaignot, C; Coste, J; Dray-Spira, R; Rey, G; Weill, A; Zureik, M, 2018)
"Diazepam 20 mg was used up to three times per day, but didn't seem to improve or reduce the anxiety, agitation, visual or auditory hallucinations."1.48Delirium tremens in an AUD patient after an intrathecal baclofen pump induced total alcohol abstinence. ( Calvo, ME; Gunnarsson, T; Hao, M; Smith, L, 2018)
"Baclofen has been shown to reduce alcohol consumption in alcohol-dependent individuals, but there is marked heterogeneity in response."1.48Moderation of baclofen response by a GABA ( Baillie, A; Dore, G; Fraser, I; Haber, PS; Luquin, N; Morley, KC; Phung, N; Trent, RJ, 2018)
"Baclofen has been associated with diverse adverse events (AEs), but the causality of these AEs has never been properly assessed."1.46Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol. ( Auffret, M; Baguet, A; Bordet, R; Cabe, N; Carton, L; Cottencin, O; Deheul, S; Dervaux, A; Dib, M; Drelon, M; Duhamel, A; Gautier, S; Grit, I; Guillin, O; Jardri, R; Kemkem, A; Labreuche, J; Lapeyre-Mestre, M; Masquelier, C; Rolland, B; Vabret, F, 2017)
"Off-label prescribing (OLP) may raise serious safety concerns that traditional spontaneous reporting of adverse drug reactions (ADRs) may not identify in a timely manner."1.46Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France. ( Auffret, M; Bordet, R; Cottencin, O; Deheul, S; Duhamel, A; Gautier, S; Labreuche, J; Rolland, B, 2017)
"Non-baclofen cases had lower rate of endotracheal intubation (n = 1833, 6%, P < 0."1.46Baclofen Self-Poisoning in the Era of Changing Indication: Multicentric Reports to a French Poison Control Centre. ( Boels, D; Brunet, M; Le Roux, G; Léger, M; Lerolle, N, 2017)
" Further randomized studies alongside investigation of dosing strategies are required."1.46A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. ( Gilmore, I; Owens, L; Pirmohamed, M; Richardson, P; Rose, A; Thompson, A, 2017)
" At a mean dosage of 40 mg/day (extremes: 30-210), the median daily alcohol consumption reduced from 80 to 0 g/day (P<0."1.46One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. ( Barrault, C; Béhar, V; Cadranel, JF; Costentin, C; Garioud, A; Hagège, H; Lison, H; Medmoun, M; Pulwermacher, G; Roudot-Thoraval, F, 2017)
"Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year."1.46The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study. ( Auffret, M; Bordet, R; Cottencin, O; Deheul, S; Duhamel, A; Gautier, S; Labreuche, J; Pignon, B; Rolland, B; Simioni, N, 2017)
"Baclofen is a new and promising pharmacological compound for the treatment of alcohol dependence (AD)."1.46Speaking fluently with baclofen? ( Beraha, E; Bodewits, P; van den Brink, W; Wiers, R, 2017)
"A 23-year-old man with a history of alcohol dependence was admitted to our hospital after self-intoxication with 2700 mg baclofen and 330 mg mirtazapine."1.43[Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms]. ( de Witte, LD; Dekker, D; Kaasjager, K; Kromkamp, M; Veraart, J; Vinkers, CH, 2016)
"We describe severe central sleep apnea (CSA) in four patients with none of the conditions commonly associated with CSA who were receiving chronic baclofen therapy for alcohol withdrawal."1.43Severe Central Sleep Apnea Associated With Chronic Baclofen Therapy: A Case Series. ( d'Ortho, MP; Gagnadoux, F; Gentina, T; Joyeux-Faure, M; Launois, SH; Olivier, PY; Pépin, JL, 2016)
"The treatment of alcohol dependence (AD) is a complex activity as the variables are numerous; however, those which must necessarily be taken into account are the type of AD, the internal comorbidities and the presence of any psychiatric comorbidity."1.43Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy. ( Borro, P; Leone, S; Testino, G, 2016)
"Baclofen seekers were more likely to be retained in treatment at 6 months (OR = 3."1.43Characteristics of Patients with Alcohol Dependence Seeking Baclofen Treatment in France: A Two-Centre Comparative Cohort Study. ( Bence, C; Cottencin, O; Deken, V; Preda, C; Rolland, B; Simioni, N, 2016)
"Baclofen has been shown to produce enantioselective effects in behavioral assays, including those modeling reflexive and sexual behavior."1.42Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption. ( Blasingame, SN; Boehm, SL; Kasten, CR, 2015)
" The mean dosage of baclofen at the onset of the first adverse effect was 83 ± 57 mg/day."1.42Tolerability of High-dose Baclofen in the Treatment of Patients with Alcohol Disorders: A Retrospective Study. ( Alexandre-Dubroeucq, C; Jaury, P; Le Jeunne, C; Legay Hoang, L; Pinot, J; Rigal, L, 2015)
"Baclofen treatment decreased craving in all patients."1.42Anticraving Effect of Baclofen in Alcohol-Dependent Patients. ( Alvarez, JC; Imbert, B; Simon, N, 2015)
" The lack of proper recommendations regarding the dosage has important implications for safety in clinical management."1.42High doses of Baclofen as suicide attempt in patients with alcohol use disorders - A serious concern. ( Baby, S; Chand, P; Gowda, GS; Holla, B; Murthy, P; Prabhu, L; Viswanath, B, 2015)
" HDB induces frequent neuropsychiatric adverse events (AEs)."1.42Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. ( Auffret, M; Bordet, R; Cottencin, O; Danel, T; Deheul, S; Gautier, S; Langlois, C; Rolland, B; Valin, T, 2015)
"Baclofen was suggested as a possible cause of the CSAS, and after its withdrawal, a second polysomnography was done, showing the disappearance of the central apneas and a shift to severe obstructive SAS (AHI 43."1.42Baclofen-Associated Onset of Central Sleep Apnea in Alcohol Use Disorder: A Case Report. ( Besson, M; Cervena, K; Claudel, E; Espa, F; Janssens, JP; Lador, F; Mégevand, P; Pépin, JL; Perogamvros, L; Thorens, G, 2015)
"We report the case of a woman with both alcohol use disorder and bulimia nervosa."1.42Efficacy of High-Dose Baclofen for Alcohol Use Disorder and Comorbid Bulimia: A Case Report. ( Bertschy, G; Lalanne, L; Riegert, M; Weibel, S, 2015)
"Baclofen has been increasingly used in the treatment of alcohol withdrawal syndrome (AWS)."1.40Increase of baclofen intoxications: risks involved and management. ( Arbouw, ME; Hoge, HL; Jansman, FG; Meulenbelt, J, 2014)
"In the alcohol dependence group, median duration of baclofen treatment was 143."1.40Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns--a cohort study. ( Dupouy, J; Fournier, JP; Jouanjus, É; Lapeyre-Mestre, M; Oustric, S; Palmaro, A; Poutrain, JC, 2014)
"Baclofen is a γ-aminobutyric acid B (GABA-B) receptor agonist that is approved for spasticity."1.40Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder. ( Bence, C; Bordet, R; Carton, L; Cottencin, O; Deheul, S; Jaillette, E; Rolland, B; Saulnier, F, 2014)
"Baclofen is a GABA-B receptor agonist used in the treatment of spasticity."1.40High variability in the exposure of baclofen in alcohol-dependent patients. ( Alvarez, JC; Grassin-Delyle, S; Imbert, B; Jaquet, I; Lançon, C; Marsot, A; Simon, N, 2014)
"Starting from 2002, an Alcohol Addiction Unit (AAU) was formed within the liver transplant center for the management of alcoholic patients affected by end-stage liver disease and included in the waiting list for transplantation."1.39Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. ( Addolorato, G; Agnes, S; Cossari, A; D'Angelo, C; Ferrulli, A; Gasbarrini, A; Gasbarrini, G; Landolfi, R; Leggio, L; Mirijello, A; Vassallo, G, 2013)
"Alcohol dependence is associated with a wide array of physical and psychiatric complications and is a major cause of morbidity and mortality worldwide."1.38High-dose baclofen for treatment-resistant alcohol dependence. ( Currie, J; Jones, DM; Pastor, A, 2012)
"Baclofen is a safe and well-tolerated novel drug treatment for alcohol dependence."1.38Baclofen for the treatment of alcohol dependence. ( Howland, RH, 2012)
"Baclofen is a gamma amino butyric acid (GABA) derivative that is a specific agonist at GABA-B receptors."1.37Baclofen-induced morbiliform rashes: a case series. ( Benegal, V; Jayaram, N; Manjunatha, N; Saddichha, S, 2011)
"Baclofen has been studied for the treatment of alcohol withdrawal, but current research is limited."1.34Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review. ( Schrader, S; Stallings, W, 2007)
"Current pharmacotherapies for alcohol dependence in humans (e."1.32Rats on the grog: novel pharmacotherapies for alcohol craving. ( Gallate, JE; McGregor, IS, 2004)
"Baclofen was orally administered for 4 weeks, at a dose of 15 mg/day refracted in three times per day for the first 3 days, with the dose increased to 30 mg/day for the remaining 27 days."1.31Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. ( Addolorato, G; Capristo, E; Caputo, F; Colombo, G; Gasbarrini, G; Gessa, GL, 2000)
"Baclofen was largely ineffective in reducing withdrawal-induced tremors, although it was capable of producing sedation of a different type than that produced by phenobarbitol and ethanol."1.26The effects of ethanol, phenobarbital, and baclofen on ethanol withdrawal in the rhesus monkey. ( Tarika, JS; Winger, G, 1980)

Research

Studies (217)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.46)18.7374
1990's4 (1.84)18.2507
2000's33 (15.21)29.6817
2010's141 (64.98)24.3611
2020's38 (17.51)2.80

Authors

AuthorsStudies
Burnette, EM1
Nieto, SJ1
Grodin, EN1
Meredith, LR1
Hurley, B1
Miotto, K1
Gillis, AJ1
Ray, LA1
Bach, P1
Tyson, LD2
Cheng, A1
Kelleher, C1
Strathie, K1
Lovendoski, J1
Habtemariam, Z1
Lewis, H2
Giri, S1
Sundaram, S1
Vannier, AGL1
Shay, JES1
Fomin, V1
Patel, SJ1
Schaefer, E1
Goodman, RP1
Luther, J1
Bauer, MR1
Hernández, M1
Kasten, CR2
Boehm, SL3
Logge, W2
Baillie, A7
Haber, P1
Towers, E2
Riordan, BC1
Morley, K3
Barrault, C4
Alqallaf, S2
Lison, H4
Lamote-Chaouche, I2
Bourcier, V2
Laugier, J2
Thevenot, T2
Labarriere, D2
Ripault, MP2
Le Gruyer, A2
Costentin, C3
Behar, V3
Hagege, H3
Jung, C2
Cadranel, JF4
Pelz, P3
Genauck, A1
Lorenz, RC2
Wüstenberg, T2
Wackerhagen, C1
Charlet, K2
Gleich, T1
Geisel, O6
Heinz, A4
Müller, CA8
Beck, A3
Agabio, R8
Saulle, R2
Rösner, S2
Minozzi, S3
Ross, H1
Harries, B1
Szelest, I1
Engelbrecht, R1
Umhau, JC1
Price, ST1
Brown, B1
Hurzeler, T1
Arunogiri, S1
Haber, PS12
Duan, F1
Zhai, H1
Liu, C1
Chang, C1
Song, S1
Li, J1
Cheng, J1
Yang, S1
Crunelle, CL1
Jegham, S1
Vanderbruggen, N1
Matthys, F1
Neven, A1
Dumont, GJH1
Liu, J1
Wang, LN1
Braillon, A7
Naudet, F7
Cristea, IA1
Lexchin, J1
Rolland, B22
Simon, N5
Franchitto, N6
Aubin, HJ5
Garbutt, JC8
Daeppen, JB1
van den Brink, W6
Logge, WB4
Baillie, AJ3
Morley, KC10
Echeverry-Alzate, V1
Jeanblanc, J1
Sauton, P1
Bloch, V2
Labat, L1
Soichot, M1
Vorspan, F2
Naassila, M1
Reynoard, J1
Schmitt, C1
Torrents, R1
Paille, F5
Kent, CN1
Park, C1
Lindsley, CW1
Andrade, C1
Holtyn, AF2
Weerts, EM2
Baldwin, DS1
Amaro, H1
Leggio, L21
Sinclair, JMA1
Marti-Prats, L1
Belin-Rauscent, A1
Fouyssac, M1
Puaud, M1
Cocker, PJ1
Everitt, BJ1
Belin, D1
Augier, E1
Reade, MC1
Vourc'h, M2
Garret, C1
Gacouin, A1
Lacherade, JC1
Jonas, M1
Klouche, K1
Ferrandiere, M1
Jaber, S1
Flet, L1
Dailly, E1
Pouplet, C1
Maamar, A1
Reignier, J1
Roquilly, A1
Feuillet, F2
Mahe, PJ2
Asehnoune, K2
Kampov-Polevoy, AB2
Pedersen, C1
Stansbury, M1
Jordan, R1
Willing, L1
Gallop, RJ1
Litten, RZ1
Boels, D3
Victorri-Vigneau, C2
Grall-Bronnec, M2
Touré, A2
Garnier, A1
Turcant, A1
Le Roux, G3
Farokhnia, M3
Schwandt, ML1
Lee, MR3
Bollinger, JW1
Farinelli, LA2
Amodio, JP1
Sewell, L1
Lionetti, TA1
Spero, DE1
Beraha, E1
Bodewits, P2
Wiers, R1
Pignon, B2
Labreuche, J6
Auffret, M12
Gautier, S11
Deheul, S12
Simioni, N2
Cottencin, O15
Bordet, R15
Duhamel, A5
Reynaud, M2
Trinquet, F1
Zakine, B1
Dano, C1
Dematteis, M1
Trojak, B1
Detilleux, M1
Beraha, EM5
Salemink, E3
Goudriaan, AE2
Wiers, RW3
Nau, JY9
Pelissier, F4
de Haro, L3
Roudot-Thoraval, F1
Garioud, A2
Medmoun, M2
Pulwermacher, G2
Kaminski, BJ1
Owens, L3
Thompson, A3
Rose, A1
Gilmore, I1
Pirmohamed, M2
Richardson, P2
Palpacuer, C1
Duprez, R1
Huneau, A1
Locher, C1
Boussageon, R1
Laviolle, B1
Larabi, IA1
Fabresse, N1
Knapp, A1
Forcet, M1
Baud, FJ1
Lorin de la Grandmaison, G1
Alvarez, JC3
Léger, M1
Brunet, M2
Lerolle, N1
Antonelli, M1
Ferrulli, A8
Sestito, L1
Vassallo, GA1
Tarli, C1
Mosoni, C1
Rando, MM1
Mirijello, A4
Gasbarrini, A2
Addolorato, G19
Caous, AS2
Gaboriau, L1
Hamel, JF1
Martinez, L1
Declèves, X1
Azuar, J1
Fortias, M1
Questel, F1
Dereux, A1
Grichy, L1
Barreteau, H1
Bellivier, F1
Lépine, JP1
Donoghue, K1
Revol, B1
Jullian-Desayes, I1
Bailly, S1
Mallaret, M1
Tamisier, R1
Agier, MS1
Lador, F2
Joyeux-Faure, M2
Pépin, JL3
Schlemm, L1
Hellweg, R4
Wiedemann, K2
Rose, AK1
Jones, A1
Costa, M1
Carrieri, P1
Bianchi, PC1
Carneiro de Oliveira, PE1
Palombo, P1
Leão, RM1
Cogo-Moreira, H1
Planeta, CDS1
Cruz, FC1
Vengeliene, V1
Takahashi, TT1
Dravolina, OA1
Belozertseva, I1
Zvartau, E1
Bespalov, AY1
Spanagel, R1
Sheskier, MB1
Le, AN1
Singley, E1
Bouhlal, S1
Ton, T1
Zhao, Z1
Fraser, I2
Furneaux-Bate, A1
Dore, G2
Roberts, M1
Abdalla, A1
Phung, N2
Pakri Mohamed, RM1
Kumar, J1
Ahmad, SU1
Mohamed, IN1
Krediet, E1
Pierce, M1
Sutterland, A1
Luquin, N1
Trent, RJ1
Calvo, ME1
Gunnarsson, T1
Smith, L1
Hao, M1
Chaignot, C1
Zureik, M1
Rey, G1
Dray-Spira, R1
Coste, J1
Weill, A1
Deschaine, SL1
Sadighi, A1
Akhlaghi, F1
Sinclair, JM2
Caputo, F6
Chick, JD1
de La Selle, P1
Heydtmann, M2
Jaury, P2
Lingford-Hughes, AR1
Pastor, A3
Paterson, LM1
Stafford, A1
de Beaurepaire, R1
Wernecke, KD2
Morris, RW1
Castrén, S1
Mäkelä, N1
Alho, H1
Rombouts, SA1
Béhal, H1
Jouanjus, E2
Lloyd-Jones, M1
Currie, J2
D'Angelo, C3
Vassallo, G1
Cossari, A1
Gasbarrini, G8
Landolfi, R1
Agnes, S1
Leung, S2
Marsot, A1
Imbert, B2
Grassin-Delyle, S1
Jaquet, I1
Lançon, C1
Pommier, P1
Debaty, G1
Bartoli, M1
Viglino, D1
Carpentier, F1
Danel, V1
Maxime, M1
Dupouy, J1
Fournier, JP1
Palmaro, A1
Poutrain, JC1
Oustric, S1
Lapeyre-Mestre, M2
Jaillette, E1
Carton, L2
Bence, C2
Saulnier, F1
Lecomte, L1
Loche, V1
Hennaux, C1
Fleury, B1
Benyamina, A2
Zywiak, WH2
Edwards, SM1
Tidey, JW1
Swift, RM6
Kenna, GA6
Smadja, J1
Paradis, M1
Pape, E1
Roman, E1
Scala-Bertola, J1
Thivilier, C1
Javot, L1
Saint-Marcoux, F1
Jouzeau, JY1
Gambier, N1
Valin, T2
Langlois, C1
Danel, T1
Arbouw, ME1
Hoge, HL1
Meulenbelt, J1
Jansman, FG1
Blasingame, SN1
Ponizovsky, AM1
Rosca, P1
Aronovich, E1
Weizman, A1
Grinshpoon, A1
Béné, J1
Soyka, M1
Lieb, M1
Besson, J1
Khazaal, Y1
Tomei, A1
Grivel, J1
Zullino, D1
Borro, P1
Leone, S1
Testino, G1
Rigal, L1
Legay Hoang, L1
Alexandre-Dubroeucq, C1
Pinot, J1
Le Jeunne, C1
Higl, V1
Krüger, J1
Stickel, A1
Holla, B1
Gowda, GS1
Prabhu, L1
Baby, S1
Viswanath, B1
Chand, P1
Murthy, P1
Krupitsky, EM2
Rybakova, KV1
Kiselev, AS1
Alexeeva, YV1
Berntsev, VA1
Chekhlaty, EI1
Zubova, EY1
Popov, YV1
Neznanov, NG1
Perogamvros, L1
Thorens, G1
Mégevand, P1
Claudel, E1
Espa, F1
Besson, M1
Cervena, K1
Janssens, JP1
Weibel, S1
Lalanne, L1
Riegert, M1
Bertschy, G1
Preda, C1
Deken, V1
Olivier, PY1
Gentina, T1
Launois, SH1
d'Ortho, MP1
Gagnadoux, F1
Journiac, K1
Pascuttini, F1
Touzeau, D1
Rivollier, F1
Masson, M1
Bole, R1
Indla, V1
Awachar, R1
Reddy, IR1
de Witte, LD1
Dekker, D1
Veraart, J1
Kromkamp, M1
Kaasjager, K1
Vinkers, CH1
Sebille, V1
Gupta, M1
Verma, P1
Rastogi, R1
Arora, S1
Elwadhi, D1
Bakker, A1
de Jong, D1
Smits, N1
Zwart, JW1
Geest, DV1
Schiphof, T1
Defourny, H1
van Tricht, M1
Dib, M1
Kemkem, A1
Grit, I1
Drelon, M1
Cabe, N1
Vabret, F1
Guillin, O1
Baguet, A1
Masquelier, C1
Dervaux, A1
Jardri, R1
Azevedo, CA1
Mammis, A1
Cardona, F1
Picot, C1
Puskarczyk, E1
Sapori, JM1
Tournoud, C1
Hauser, P1
Fuller, B1
Ho, SB1
Thuras, P1
Kern, S1
Dieperink, E1
Goh, ET1
Morgan, MY1
Shah, R1
Singla, H1
Maccioni, P2
Fantini, N1
Froestl, W1
Carai, MA4
Gessa, GL6
Colombo, G7
Cardone, S5
Malandrino, N2
Vonghia, L2
Miceli, A3
Capristo, E3
Hadengue, A1
Gache, P2
Kiefer, F1
Johnson, BA2
Gallop, R1
Kalka-Juhl, L1
Flannery, BA2
Soufia, M1
Plaze, M1
Gueguen, B1
Demigneux, G1
Olié, JP1
Gaillard, R1
Saddichha, S1
Jayaram, N1
Manjunatha, N1
Benegal, V1
Ameisen, O3
Nesci, A1
Canestrelli, B1
Monteleone, P1
Enserink, M1
Macaigne, G1
Champagnon, N1
Harnois, F1
Cheiab, S1
Chayette, C1
Amato, L1
Davoli, M1
Lyon, JE1
Khan, RA1
Gessert, CE1
Larson, PM1
Renier, CM1
Helland, A1
Bramness, JG1
Muzyk, AJ1
Rivelli, SK1
Gagliardi, JP1
Zambon, A2
Jones, DM1
Le Strat, Y1
Gorsane, MA1
Kebir, O1
Hache, G1
Blecha, L1
Howland, RH1
Peters, S1
Slattery, DA1
Flor, PJ1
Neumann, ID1
Reber, SO1
McGeary, JE1
Edwards, S1
Fricchione, SR1
Shoaff, JR1
Serra, S2
Brunetti, G1
Vacca, G2
McGregor, IS1
Gallate, JE1
Kaplan, GB1
McRoberts, RL1
Smokler, HJ1
Pibiri, F1
Cody, MW1
Renn, W1
Grace, K1
Osborne, M1
Crosby, K1
Morreale, M1
Trivette, A1
Abenavoli, L2
Heilig, M1
Egli, M1
Walker, BM1
Koob, GF1
Marras, P1
Carpiniello, B1
Moore, EM1
Serio, KM1
Goldfarb, KJ1
Stepanovska, S1
Linsenbardt, DN1
Vignoli, T1
Francini, S1
Stoppo, M1
Bernardi, M1
Stallings, W1
Schrader, S1
Ozsoy, S1
Esel, E1
Turan, T1
Kula, M1
Flannery, B1
Quintanilla, ME1
Perez, E1
Tampier, L1
Tarika, JS1
Winger, G1
Krupitskiĭ, EM2
Burakov, AM3
Ivanov, VB2
Karandashova, GF1
Lapin, IP2
Grinenko, AIa2
Borodkin, IuS2
Krandashova, GF1
Vescovi, PP2
Volpi, R1
Coiro, V2
Lobina, C1
Pani, M1
Reali, R1

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU: Study Protocol for a Randomised Controlled Against Placebo Trial[NCT02723383]Phase 3314 participants (Actual)Interventional2016-06-27Completed
A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics[NCT01751386]Phase 239 participants (Actual)Interventional2012-12-03Completed
Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease[NCT01711125]Phase 3104 participants (Actual)Interventional2013-03-31Completed
Modification of Pavlovian and Instrumental Learning in Human Addiction[NCT04032587]80 participants (Anticipated)Interventional2019-10-01Recruiting
Baclofen for the Treatment of Alcohol Dependence - BACLAD[NCT01266655]Phase 2/Phase 356 participants (Actual)Interventional2011-02-28Completed
A Pilot Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking[NCT01076283]Phase 214 participants (Actual)Interventional2009-12-31Completed
Effects of Ghrelin on Alcohol Cue Reactivity and Craving[NCT01190085]45 participants (Actual)Interventional2011-04-30Completed
A Novel Compound for Alcoholism Treatment: A Translational Strategy[NCT02039349]Phase 114 participants (Actual)Interventional2014-01-03Completed
Effects of Ghrelin on Alcohol Administration in Non-Treatment Seeking Heavy Drinkers[NCT01779024]Phase 217 participants (Actual)Interventional2012-12-13Completed
Prospective Assessment of Valproate on Ethanol Withdrawal[NCT03235531]Phase 4210 participants (Anticipated)Interventional2017-07-11Recruiting
Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety: an Experimental Medicine Study[NCT01187511]Phase 244 participants (Actual)Interventional2010-01-31Completed
Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics[NCT01227980]Phase 270 participants (Actual)Interventional2010-10-31Completed
Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics[NCT00605904]Phase 237 participants (Actual)Interventional2008-01-31Completed
Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study[NCT00525252]Phase 1/Phase 286 participants Interventional2003-02-28Completed
Spironolactone in Alcohol Use Disorder (SAUD): A Double-Blind, Placebo-Controlled, Ascending Dose, Phase 1b Study[NCT05807139]Phase 120 participants (Anticipated)Interventional2024-01-03Recruiting
Treating Alcohol Withdrawal With Oral Baclofen: a Randomized, Double Blind, Placebo Controlled Trial[NCT00597701]79 participants (Actual)Interventional2003-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session

Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL. (NCT01751386)
Timeframe: 2 hours

Interventionmini-drinks (Mean)
Baclofen4.11
Placebo4.5

Alcohol Drinking

"Whether baclofen, as compared to active placebo, results in lower quantity of alcohol consumed during the Alcohol Self-Administration (ASA).~Consistent with O'Malley et al. 2002, the ASA paradigm allows to use a fixed-dose (the priming drink), followed by a 2-hour free-choice phase when subjects may choose to drink or not up to 8 mini-drinks. Participants receive a monetary compensation of $3 dollars per each mini-drink not consumed; therefore the amount of minidrinks consumed during the 2-hour sessions ranges 0-8, and the monetary compensation ranges $0-24. The quantity of alcohol consumed during the free-choice session is expressed as standard drinking unit, where a standard drink unit contains about 14 grams of pure alcohol (about 0.6 fluid ounces or 1.2 tablespoons)." (NCT01076283)
Timeframe: approximately 8 days after drug administration

Interventionstandard drinking units (Mean)
Baclofen0.17
Cyproheptadine1.43

Alcohol Urge

"Whether baclofen, as compared to active placebo, results in diminished cue-reactivity responses to alcohol cues in terms of urge to drink [as measured by the Alcohol Urge Questionnaire (AUQ)] during the Cue Reactivity.~The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from strongly disagree to strongly agree. Each item is scored on a 1 to 7 scale (Strongly Disagree = 1 and Strongly Agree = 7). Items 2 and 7 are reverse scored. A total score is computed by summing the item scores and ranges from 8 (lowest craving value) to 56 (highest craving value). Higher scores reflect greater craving (i.e. worse outcome)." (NCT01076283)
Timeframe: approximately 8 days after drug administration

Interventionunits on a scale (Mean)
Baclofen22.5
Cyproheptadine19.4

Alcohol Visual Analogue Scale (A-VAS)

"Whether ghrelin intravenous (i.v.), as compared to saline i.v., dose-dependently results in increased cue-reactivity (CR) responses to alcohol cues in terms of urge to drink [as measured by the Alcohol Visual Analogue Scale (A-VAS)].~The A-VAS was rated on 11-point anchored Likert-type scales, where 0 is the minimum score (no craving) and 11 is the maximum score (highest craving intensity). The change in the A-VAS score (deltaA-VAS) was used to indicate decrease (-d) or increase (+d) in craving intensity." (NCT01190085)
Timeframe: approximately 30 minutes after drug administration

Interventionunits on a scale (Mean)
Ghrelin (1 Microg/kg)1.95
Ghrelin (3 Microg/kg)2.66
Saline Solution4.29

Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability.

Whether ghrelin intravenous (i.v.), as compared to saline i.v., does not significantly increase Adverse Events (AEs). (NCT01190085)
Timeframe: participants will be followed after the cue-reactivity experiment, an expected average of 7 days

Interventionparticipants (Number)
Ghrelin (1 Microg/kg)11
Ghrelin (3 Microg/kg)12
Saline Solution15

Salivation

Whether ghrelin intravenous (i.v.), as compared to saline i.v., dose-dependently results in increased cue-reactivity (CR) responses to alcohol cues in terms of psychophysiological responses, namely salivation changes. (NCT01190085)
Timeframe: approximately 30 minutes after drug administration

Interventiongram (Mean)
Ghrelin (1 Microg/kg)1.8
Ghrelin (3 Microg/kg)1.9
Saline Solution3.2

Alcohol Infusions Self-administered

The total number of alcohol infusions self-administered. (NCT01779024)
Timeframe: 120 minutes after the start of the infusion

InterventionNumber of alcohol infusions (Mean)
Ghrelin10.45
Placebo8.80

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167911.6932
Placebo14.6126

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616798.7646
Placebo10.413

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167911.4075
Placebo13.0412

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616799.6218
Placebo12.1841

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167913.9789
Placebo15.946

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616799.9075
Placebo12.1841

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616799.6218
Placebo11.6603

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616798.9075
Placebo13.1841

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167912.1376
Placebo13.1086

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616799.7805
Placebo10.6194

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167911.7091
Placebo13.1432

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167911.3519
Placebo12.1432

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167914.1376
Placebo16.9051

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167911.2805
Placebo12.0956

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167912.2091
Placebo10.3813

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167913.1376
Placebo10.0004

Alcohol Craving in Response to the Trier/Cue-reactivity Procedure

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 100 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167912.977
Placebo12.0475

Alcohol Craving in Response to the Trier/Cue-reactivity Procedure

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167915.1645
Placebo12.0116

Alcohol Craving in Response to the Trier/Cue-reactivity Procedure

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 20 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167918.4145
Placebo15.2497

Alcohol Craving in Response to the Trier/Cue-reactivity Procedure

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 40 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167920.352
Placebo18.0116

Alcohol Craving in Response to the Trier/Cue-reactivity Procedure

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 70 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167913.7895
Placebo13.0592

Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period

Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616797.8582
Placebo8.7076

Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period

Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616796.4777
Placebo7.041

Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period

Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616796.5443
Placebo6.6122

Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period

Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616796.011
Placebo5.4219

Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period

Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616796.611
Placebo5.7835

Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period

Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616795.3112
Placebo5.1362

Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period

Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616797.2231
Placebo4.5648

Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period

Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616795.2365
Placebo4.2791

Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period

Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616796.6777
Placebo5.9457

Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period

Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616796.6078
Placebo6.66

Depression Symptom Ratings Measured Bi-weekly During the Treatment Period

Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK56167910.002
Placebo8.7759

Depression Symptom Ratings Measured Bi-weekly During the Treatment Period

Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616796.3187
Placebo6.2997

Depression Symptom Ratings Measured Bi-weekly During the Treatment Period

Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616797.6521
Placebo8.0633

Depression Symptom Ratings Measured Bi-weekly During the Treatment Period

Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616798.0521
Placebo6.5855

Depression Symptom Ratings Measured Bi-weekly During the Treatment Period

Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616797.0521
Placebo5.9353

Depression Symptom Ratings Measured Bi-weekly During the Treatment Period

Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616794.8092
Placebo4.9188

Depression Symptom Ratings Measured Bi-weekly During the Treatment Period

Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616797.149
Placebo4.2997

Depression Symptom Ratings Measured Bi-weekly During the Treatment Period

Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616794.8071
Placebo4.2045

Depression Symptom Ratings Measured Bi-weekly During the Treatment Period

Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616798.2521
Placebo7.1569

Depression Symptom Ratings Measured Bi-weekly During the Treatment Period

Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616796.6366
Placebo6.9188

Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 1 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616799.5572
Placebo12.2152

Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 11 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616797.7
Placebo8.8468

Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 14 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616795.7
Placebo7.3205

Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 18 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616796.2715
Placebo6.9521

Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 21 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616795.2715
Placebo6.531

Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 25 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616794.6286
Placebo6.6363

Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 28 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616793.6083
Placebo6.5836

Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 32 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616793.7666
Placebo6.531

Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 4 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616797.9858
Placebo9.7942

Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 7 of the treatment period

InterventionUnits on a scale (Least Squares Mean)
GSK5616798.1286
Placebo8.7942

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

InterventionUnits on a scale (Mean)
Pexacerfont16.6
Placebo12.9

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

InterventionUnits on a scale (Mean)
Pexacerfont12.7
Placebo10.7

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont16.5
Placebo11.8

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont15
Placebo12.1

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont18.7
Placebo14.5

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont13.7
Placebo12.3

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont13.5
Placebo12

Alcohol Craving in Response to the Alcohol Cue Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont13.7
Placebo11.7

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont16.8
Placebo12.5

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont12.9
Placebo10.2

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont15.3
Placebo12.2

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont14.9
Placebo11.6

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont17.8
Placebo14.4

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont14.3
Placebo11.6

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Interventionunits on a scale (Mean)
Pexacerfont14.9
Placebo11.7

Alcohol Craving in Response to the Stress Script

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

InterventionUnits on a scale (Mean)
Pexacerfont14.6
Placebo11.2

Alcohol Craving Rating in Response to Meta-Chlorophenylpiperazine

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion

InterventionUnits on a scale (Mean)
Acamprosate3.460
Placebo5.416

Alcohol Craving Rating in Response to Saline Infusion

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion

InterventionUnits on a scale (Mean)
Acamprosate1.704
Placebo1.766

Alcohol Craving Rating in Response to Yohimbine Infusion

Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion

InterventionUnits on a scale (Mean)
Acamprosate3.613
Placebo3.606

Benzodiazepine Doses Used to Treat Acutely-withdrawing Alcoholic Patients in the Baclofen-treated and Placebo-treated Groups

In acutely-withdrawing alcoholic patients treated with either baclofen or placebo, symptom-driven benzodiazepine doses were assessed for the 72 hours following the first Clinical Institute Withdrawal Assessment (CIWA) score of 11 or greater. (NCT00597701)
Timeframe: From eligibility for randomization (Clinical Institute Withdrawal Assessment [CIWA] score of at least 11) until 72 hours of observation had been completed.

Interventionmg of benzodiazepine per 8 hours (Mean)
Baclofen14.1
Placebo124.4

Reviews

39 reviews available for baclofen and Alcohol Abuse

ArticleYear
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
    Drugs, 2022, Volume: 82, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Humans; Naltrexone; Topiramate

2022
    MMW Fortschritte der Medizin, 2022, Volume: 164, Issue:7

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans

2022
Baclofen for alcohol use disorder.
    The Cochrane database of systematic reviews, 2023, 01-13, Volume: 1

    Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Baclofen; Chronic Disease; Female; Humans; Male; M

2023
Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases.
    Journal of psychiatric research, 2023, Volume: 164

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Craving; Humans; Liver Diseases

2023
[The efficacy of baclofen in alcohol dependence].
    Tijdschrift voor psychiatrie, 2019, Volume: 61, Issue:8

    Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Treatment Outcome

2019
Baclofen for alcohol withdrawal.
    The Cochrane database of systematic reviews, 2019, 11-06, Volume: 2019, Issue:11

    Topics: Alcoholism; Baclofen; Craving; GABA Agonists; Humans; Randomized Controlled Trials as Topic; Substan

2019
Toxicological considerations in the prescription of baclofen for the treatment of substance use disorders.
    Expert opinion on drug metabolism & toxicology, 2020, Volume: 16, Issue:4

    Topics: Alcoholism; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor Agonists; Humans; Off-Label

2020
Classics in Chemical Neuroscience: Baclofen.
    ACS chemical neuroscience, 2020, 06-17, Volume: 11, Issue:12

    Topics: Alcoholism; Baclofen; Brain; gamma-Aminobutyric Acid; Humans; Neurosciences; Receptors, GABA-B

2020
Individualized, High-Dose Baclofen for Reduction in Alcohol Intake in Persons With High Levels of Consumption.
    The Journal of clinical psychiatry, 2020, 08-04, Volume: 81, Issue:4

    Topics: Alcohol Drinking; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Meta-Analysis as Topic

2020
The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis.
    Neuroscience and biobehavioral reviews, 2021, Volume: 125

    Topics: Alcohol Drinking; Alcoholism; Anxiety; Baclofen; GABA-B Receptor Agonists; Humans

2021
Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2021, Feb-24, Volume: 56, Issue:2

    Topics: Acetamides; Alcoholism; Animals; Baclofen; Bacterial Proteins; GABA-B Receptor Agonists; Mice; Rats;

2021
GABA
    Current topics in behavioral neurosciences, 2022, Volume: 52

    Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Receptors, GABA-B; Substance Withdrawal Synd

2022
Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2017, Volume: 27, Issue:11

    Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Observational Studies as Topic

2017
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Addiction (Abingdon, England), 2018, Volume: 113, Issue:2

    Topics: Acamprosate; Alcoholism; Baclofen; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topirama

2018
Alcohol addiction - the safety of available approved treatment options.
    Expert opinion on drug safety, 2018, Volume: 17, Issue:2

    Topics: Alcohol Deterrents; Alcoholism; Baclofen; Dose-Response Relationship, Drug; Drug Approval; Europe; F

2018
Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis.
    Addiction (Abingdon, England), 2018, Volume: 113, Issue:8

    Topics: Affect; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; Depression; GA

2018
Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.
    Current drug targets, 2018, Volume: 19, Issue:12

    Topics: Alcohol Deterrents; Alcoholism; Animals; Aripiprazole; Baclofen; Cyclopentanes; Gabapentin; Humans;

2018
Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2018, Volume: 28, Issue:7

    Topics: Alcoholism; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor Agonists; Humans

2018
Baclofen for alcohol use disorder.
    The Cochrane database of systematic reviews, 2018, Nov-26, Volume: 11

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Craving; Depression; Female

2018
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
    Current opinion in psychiatry, 2019, Volume: 32, Issue:4

    Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapent

2019
Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013.
    Prescrire international, 2013, Volume: 22, Issue:141

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Clinical Trials as Topic; Dose-Response Relationship, Drug;

2013
[New treatment options for alcohol dependence].
    MMW Fortschritte der Medizin, 2013, May-02, Volume: 155, Issue:8

    Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone;

2013
Recent Developments in Pharmacotherapy of Alcoholism.
    Pharmacopsychiatry, 2015, Volume: 48, Issue:4-5

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Na

2015
Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment.
    Expert opinion on drug safety, 2016, Volume: 15, Issue:6

    Topics: Alcohol Drinking; Alcoholism; Algorithms; Baclofen; Dose-Response Relationship, Drug; GABA-B Recepto

2016
Neuromodulation Therapies for Alcohol Addiction: A Literature Review.
    Neuromodulation : journal of the International Neuromodulation Society, 2018, Volume: 21, Issue:2

    Topics: Alcoholism; Animals; Baclofen; Deep Brain Stimulation; Humans; Neurotransmitter Agents; Transcranial

2018
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:7

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Huma

2017
The state of pharmacotherapy for the treatment of alcohol dependence.
    Journal of substance abuse treatment, 2009, Volume: 36, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations

2009
Role of the GABA(B) receptor in alcohol-seeking and drinking behavior.
    Alcohol (Fayetteville, N.Y.), 2009, Volume: 43, Issue:7

    Topics: Alcohol Drinking; Alcoholism; Allosteric Regulation; Animals; Baclofen; Cyclopentanes; GABA Modulato

2009
Effectiveness and safety of baclofen in the treatment of alcohol dependent patients.
    CNS & neurological disorders drug targets, 2010, Volume: 9, Issue:1

    Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Baclofen; Brain; Brain Chemistry; Cl

2010
Safety and efficacy of baclofen in the treatment of alcohol-dependent patients.
    Current pharmaceutical design, 2010, Volume: 16, Issue:19

    Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; GABA Agonists; GABA-B Receptor Agonists; Humans; Re

2010
Medication treatment of different types of alcoholism.
    The American journal of psychiatry, 2010, Volume: 167, Issue:6

    Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female;

2010
Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome.
    The Cochrane database of systematic reviews, 2011, Jun-15, Issue:6

    Topics: Alcohol Withdrawal Seizures; Alcoholism; Anticonvulsants; Baclofen; Benzodiazepines; Ethanol; Humans

2011
[Baclofen: the new miracle cure for alcoholism?].
    Revue medicale suisse, 2011, Jul-13, Volume: 7, Issue:302

    Topics: Alcoholism; Animals; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor Agonists; Humans; R

2011
Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence.
    CNS drugs, 2012, Jan-01, Volume: 26, Issue:1

    Topics: Alcoholism; Animals; Baclofen; Evidence-Based Medicine; GABA-B Receptor Agonists; Humans; Randomized

2012
Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates.
    Substance abuse, 2012, Volume: 33, Issue:4

    Topics: Alcoholism; Animals; Baclofen; Behavior, Addictive; Clinical Trials as Topic; Disease Management; Di

2012
Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics.
    Neurotoxicity research, 2004, Volume: 6, Issue:5

    Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Clinical Trials as Topic; Ethanol; GABA Agonists; H

2004
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Pharmacology & therapeutics, 2006, Volume: 111, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis

2006
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Pharmacology & therapeutics, 2006, Volume: 111, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis

2006
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Pharmacology & therapeutics, 2006, Volume: 111, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis

2006
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Pharmacology & therapeutics, 2006, Volume: 111, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis

2006
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Pharmacology & therapeutics, 2006, Volume: 111, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis

2006
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Pharmacology & therapeutics, 2006, Volume: 111, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis

2006
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Pharmacology & therapeutics, 2006, Volume: 111, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis

2006
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Pharmacology & therapeutics, 2006, Volume: 111, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis

2006
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
    Pharmacology & therapeutics, 2006, Volume: 111, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis

2006
Baclofen: a new drug for the treatment of alcohol dependence.
    International journal of clinical practice, 2006, Volume: 60, Issue:8

    Topics: Alcoholism; Baclofen; GABA Agonists; Humans; Secondary Prevention

2006
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
    Biochemical pharmacology, 2008, Jan-01, Volume: 75, Issue:1

    Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; R

2008

Trials

42 trials available for baclofen and Alcohol Abuse

ArticleYear
Sex differences in the interrelations between stress, craving and alcohol consumption across individuals and time during baclofen treatment for alcohol dependence.
    Addictive behaviors, 2023, Volume: 136

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Craving; Female; Humans; Male; Sex Characteristics

2023
Effects of baclofen on insular gain anticipation in alcohol-dependent patients - a randomized, placebo-controlled, pharmaco-fMRI pilot trial.
    Psychopharmacology, 2023, Volume: 240, Issue:1

    Topics: Alcoholism; Anticipation, Psychological; Baclofen; Central Nervous System Depressants; Ethanol; Huma

2023
Hypothalamic-pituitary-adrenocortical response in alcohol-dependent patients during baclofen treatment and association with clinical outcome: Preliminary results.
    Alcohol (Fayetteville, N.Y.), 2023, Volume: 112

    Topics: Alcoholism; Baclofen; Ethanol; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Pituitary-Adr

2023
Baclofen during alcohol detoxification reduces the need for additional diazepam: a randomized placebo-controlled trial.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2023, Sep-09, Volume: 58, Issue:5

    Topics: Alcoholism; Baclofen; Benzodiazepines; Diazepam; Double-Blind Method; Humans; Single-Blind Method; S

2023
Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals.
    Human psychopharmacology, 2020, Volume: 35, Issue:2

    Topics: Alcoholism; Baclofen; Craving; Cues; Dose-Response Relationship, Drug; Female; GABA-B Receptor Agoni

2020
Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation: A Randomized Clinical Trial.
    JAMA, 2021, 02-23, Volume: 325, Issue:8

    Topics: Adult; Aged; Alcohol-Induced Disorders; Alcoholism; Baclofen; Double-Blind Method; Female; GABA-B Re

2021
Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021, Volume: 46, Issue:13

    Topics: Alcoholism; Baclofen; Double-Blind Method; Female; Humans; Male; Middle Aged; Treatment Outcome

2021
Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study.
    Translational psychiatry, 2017, 04-25, Volume: 7, Issue:4

    Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Biobehavioral Sciences; Craving; Double-Blin

2017
A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2017, Jul-01, Volume: 52, Issue:4

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Craving; Double-Blind Method; Female; GABA-B Receptor

2017
Hypothalamic-Pituitary-Adrenocortical Axis Activity in Alcohol-Dependent Patients During Treatment with High-Dose Baclofen.
    Pharmacopsychiatry, 2019, Volume: 52, Issue:1

    Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Alcoholism; Baclofen; Double-Blind Method; Fem

2019
Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment.
    Neuropharmacology, 2018, 07-15, Volume: 137

    Topics: Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Baclofen; Biomarkers; Double-Blind Method; F

2018
Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial.
    The British journal of psychiatry : the journal of mental science, 2018, Volume: 212, Issue:6

    Topics: Adult; Alcoholism; Baclofen; Double-Blind Method; Female; GABA-B Receptor Agonists; Humans; Liver Di

2018
Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?
    Journal of psychopharmacology (Oxford, England), 2018, Volume: 32, Issue:8

    Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Anxiety Disorders; Attentional Bias;

2018
Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2018, Volume: 28, Issue:11

    Topics: Adult; Alcoholism; Baclofen; Brain; Cues; Double-Blind Method; Female; GABA-B Receptor Agonists; Hum

2018
Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2018, Volume: 28, Issue:11

    Topics: Adult; Alcoholism; Baclofen; Brain; Cues; Double-Blind Method; Female; GABA-B Receptor Agonists; Hum

2018
Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2018, Volume: 28, Issue:11

    Topics: Adult; Alcoholism; Baclofen; Brain; Cues; Double-Blind Method; Female; GABA-B Receptor Agonists; Hum

2018
Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2018, Volume: 28, Issue:11

    Topics: Adult; Alcoholism; Baclofen; Brain; Cues; Double-Blind Method; Female; GABA-B Receptor Agonists; Hum

2018
A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation.
    Molecular psychiatry, 2021, Volume: 26, Issue:2

    Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Laboratories; Receptors, GABA-B

2021
Executive Functioning Moderates Responses to Appetitive Cues: A Study in Severe Alcohol Use Disorder and Alcoholic Liver Disease.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2019, Jan-01, Volume: 54, Issue:1

    Topics: Adult; Aged; Alcoholism; Baclofen; Cues; Double-Blind Method; Executive Function; Female; GABA-B Rec

2019
Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen.
    Psychiatry research, 2019, Volume: 272

    Topics: Acylation; Adult; Alcoholism; Baclofen; Biomarkers; Double-Blind Method; Female; GABA-B Receptor Ago

2019
Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals.
    Psychopharmacology, 2021, Volume: 238, Issue:5

    Topics: Adult; Alcoholism; Baclofen; Brain; Craving; Cues; Double-Blind Method; Female; Humans; Magnetic Res

2021
Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2019, May-01, Volume: 54, Issue:3

    Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; Dose-Response Rel

2019
The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial.
    Contemporary clinical trials, 2013, Volume: 36, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Clinical Protocols; Double-Blind Method; Drug Administration

2013
A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers.
    Psychopharmacology, 2015, Volume: 232, Issue:1

    Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St

2015
Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2014, Volume: 49, Issue:6

    Topics: Adult; Alcohol Abstinence; Alcoholism; Anxiety; Baclofen; Double-Blind Method; Female; GABA-B Recept

2014
Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up.
    Journal of substance abuse treatment, 2015, Volume: 52

    Topics: Adult; Alcoholism; Baclofen; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studi

2015
High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2015, Volume: 25, Issue:8

    Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Baclofen; Double-Blind Method; Female; Fo

2015
[Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:6

    Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Depression; Double-Blind M

2015
Serum levels of brain-derived neurotrophic factor in alcohol-dependent patients receiving high-dose baclofen.
    Psychiatry research, 2016, 06-30, Volume: 240

    Topics: Adult; Alcoholism; Baclofen; Brain-Derived Neurotrophic Factor; Double-Blind Method; Female; GABA-B

2016
Baclofen to prevent agitation in alcohol-addicted patients in the ICU: study protocol for a randomised controlled trial.
    Trials, 2016, 08-19, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Alcoholism; Baclofen; Clinical Protocols; Double-Blind Method; Female; Huma

2016
Randomized open-label trial of baclofen for relapse prevention in alcohol dependence.
    The American journal of drug and alcohol abuse, 2017, Volume: 43, Issue:3

    Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; GABA-B Receptor

2017
Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2016, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Alcoholism; Baclofen; Dose-Response Relationship, Drug; Double-Blind Method

2016
The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial.
    Addiction (Abingdon, England), 2017, Volume: 112, Issue:7

    Topics: Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up Studies; GABA-B Receptor Agonists; Hepa

2017
Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial.
    Alcoholism, clinical and experimental research, 2010, Volume: 34, Issue:11

    Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Depression; Double-Blind Method;

2010
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
    Addiction biology, 2012, Volume: 17, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female;

2012
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
    Addiction biology, 2012, Volume: 17, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female;

2012
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
    Addiction biology, 2012, Volume: 17, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female;

2012
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
    Addiction biology, 2012, Volume: 17, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female;

2012
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
    Addiction biology, 2012, Volume: 17, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female;

2012
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
    Addiction biology, 2012, Volume: 17, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female;

2012
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
    Addiction biology, 2012, Volume: 17, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female;

2012
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
    Addiction biology, 2012, Volume: 17, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female;

2012
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
    Addiction biology, 2012, Volume: 17, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female;

2012
Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial.
    Journal of hospital medicine, 2011, Volume: 6, Issue:8

    Topics: Administration, Oral; Adult; Alcoholism; Baclofen; Double-Blind Method; Female; Humans; Male; Middle

2011
Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection.
    Addictive behaviors, 2012, Volume: 37, Issue:4

    Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Female; GABA-B Receptor Agonists;

2012
A human laboratory pilot study with baclofen in alcoholic individuals.
    Pharmacology, biochemistry, and behavior, 2013, Volume: 103, Issue:4

    Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St

2013
A human laboratory pilot study with baclofen in alcoholic individuals.
    Pharmacology, biochemistry, and behavior, 2013, Volume: 103, Issue:4

    Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St

2013
A human laboratory pilot study with baclofen in alcoholic individuals.
    Pharmacology, biochemistry, and behavior, 2013, Volume: 103, Issue:4

    Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St

2013
A human laboratory pilot study with baclofen in alcoholic individuals.
    Pharmacology, biochemistry, and behavior, 2013, Volume: 103, Issue:4

    Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St

2013
Baclofen for alcohol dependence: a preliminary open-label study.
    Alcoholism, clinical and experimental research, 2004, Volume: 28, Issue:10

    Topics: Adult; Alcoholism; Baclofen; Female; Humans; Male; Middle Aged

2004
Baclofen for alcoholism.
    Lancet (London, England), 2007, Dec-08, Volume: 370, Issue:9603

    Topics: Alcoholism; Baclofen; GABA Agonists; Humans; Liver Cirrhosis, Alcoholic; Patient Selection; Temperan

2007
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
    Lancet (London, England), 2007, Dec-08, Volume: 370, Issue:9603

    Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid

2007
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
    Lancet (London, England), 2007, Dec-08, Volume: 370, Issue:9603

    Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid

2007
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
    Lancet (London, England), 2007, Dec-08, Volume: 370, Issue:9603

    Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid

2007
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
    Lancet (London, England), 2007, Dec-08, Volume: 370, Issue:9603

    Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid

2007
Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study.
    Alcohol (Fayetteville, N.Y.), 2008, Volume: 42, Issue:5

    Topics: Alcoholism; Aldosterone; Baclofen; Behavior, Addictive; Counseling; Female; Humans; Longitudinal Stu

2008
[The use of baclofen for treating affective disorders in alcoholism].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1994, Volume: 94, Issue:1

    Topics: Adult; Alcoholism; Amitriptyline; Baclofen; Diazepam; Drug Evaluation; Humans; Ligands; Mood Disorde

1994
Baclofen administration for the treatment of affective disorders in alcoholic patients.
    Drug and alcohol dependence, 1993, Volume: 33, Issue:2

    Topics: Administration, Oral; Adult; Alcoholism; Amitriptyline; Anxiety Disorders; Baclofen; Blood Platelets

1993
[Effect of pharmacotherapy of affective disorders on the psycho-semantics of alcoholic patients].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1995, Volume: 95, Issue:6

    Topics: Alcoholism; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Baclofen; Color Pe

1995

Other Studies

136 other studies available for baclofen and Alcohol Abuse

ArticleYear
Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
    European journal of gastroenterology & hepatology, 2022, 05-01, Volume: 34, Issue:5

    Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Retrospective Studies

2022
Acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?
    European journal of gastroenterology & hepatology, 2022, 06-01, Volume: 34, Issue:6

    Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis

2022
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
    JAMA network open, 2022, 05-02, Volume: 5, Issue:5

    Topics: Alcoholism; Baclofen; Female; Gabapentin; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Nal

2022
Systemic administration of racemic baclofen reduces both acquisition and maintenance of alcohol consumption in male and female mice.
    Alcohol (Fayetteville, N.Y.), 2022, Volume: 103

    Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Ethanol; Female; GABA-B Receptor Agonists; Male; Mi

2022
Response to 'acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?'
    European journal of gastroenterology & hepatology, 2022, 09-01, Volume: 34, Issue:9

    Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis

2022
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2023, Mar-10, Volume: 58, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia

2023
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2023, Mar-10, Volume: 58, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia

2023
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2023, Mar-10, Volume: 58, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia

2023
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2023, Mar-10, Volume: 58, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia

2023
Incorporating ondansetron and baclofen in alcohol use disorder treatment.
    CJEM, 2023, Volume: 25, Issue:3

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Ondansetron

2023
Baclofen for the Treatment of Alcohol Use Disorder.
    American family physician, 2023, Volume: 107, Issue:5

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans

2023
Baclofen and Alcohol Use Disorders: Breakthrough or Great White Elephant?
    Alcohol and alcoholism (Oxford, Oxfordshire), 2020, Feb-07, Volume: 55, Issue:1

    Topics: Alcoholism; Baclofen; Drug Approval; France; GABA-B Receptor Agonists; History, 21st Century; Humans

2020
France Grants an Approval to Baclofen for Alcohol Dependence.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2020, Feb-07, Volume: 55, Issue:1

    Topics: Alcoholism; Baclofen; Drug Approval; France; GABA-B Receptor Agonists; History, 21st Century; Humans

2020
Approval of Baclofen for Alcohol Use Disorders in France: A Perspective From the United States.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2020, Feb-07, Volume: 55, Issue:1

    Topics: Alcoholism; Baclofen; Drug Approval; Female; France; GABA-B Receptor Agonists; Humans; Male; Meta-An

2020
    Revue medicale suisse, 2019, Nov-27, Volume: 15, Issue:673

    Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans

2019
Baclofen: A Game Changer in the Treatment of Alcohol Dependence.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2020, Feb-07, Volume: 55, Issue:1

    Topics: Alcoholism; Baclofen; Drug Approval; France; GABA-B Receptor Agonists; Health Services Accessibility

2020
Is R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side.
    Addiction biology, 2021, Volume: 26, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor A

2021
[Medical management of alcohol use disorders].
    La Revue du praticien, 2019, Volume: 69, Issue:8

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Humans

2019
GABA
    Current topics in behavioral neurosciences, 2022, Volume: 52

    Topics: Alcoholism; Allosteric Regulation; Animals; Baclofen; Rats; Receptors, GABA-B; Substance Withdrawal

2022
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit.
    The Journal of clinical psychiatry, 2021, 01-12, Volume: 82, Issue:1

    Topics: Alcohol Drinking; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans

2021
Baclofen decreases compulsive alcohol drinking in rats characterized by reduced levels of GAT-3 in the central amygdala.
    Addiction biology, 2021, Volume: 26, Issue:4

    Topics: Alcoholism; Animals; Baclofen; Central Amygdaloid Nucleus; Compulsive Behavior; Conditioning, Operan

2021
Baclofen to Prevent Agitation Caused by Alcohol Withdrawal in the ICU.
    JAMA, 2021, 02-23, Volume: 325, Issue:8

    Topics: Alcoholism; Baclofen; Humans; Intensive Care Units; Respiration, Artificial; Substance Withdrawal Sy

2021
[Baclofen in the treatment of alcohol addiction : a French saga].
    Revue medicale suisse, 2021, Jun-09, Volume: 17, Issue:742

    Topics: Alcoholism; Baclofen; France; Humans; Medicine; Off-Label Use

2021
The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: why these findings matter.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021, Volume: 46, Issue:13

    Topics: Alcoholism; Baclofen; GABA Agonists; GABA-B Receptor Agonists; Humans; Receptors, GABA-B

2021
Baclofen and Alcohol-Dependent Patients: A Real Risk of Severe Self-Poisoning.
    Basic & clinical pharmacology & toxicology, 2017, Volume: 121, Issue:4

    Topics: Adult; Alcoholism; Baclofen; Cardiovascular Diseases; Craving; Female; France; GABA-B Receptor Agoni

2017
Speaking fluently with baclofen?
    BMJ case reports, 2017, May-11, Volume: 2017

    Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; GABA-B Receptor Agonists; Human

2017
The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study.
    Human psychopharmacology, 2017, Volume: 32, Issue:4

    Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Dose-Response Relationship, Drug;

2017
Baclofen and alcohol use disorders: From miracle to mirage.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2017, Volume: 27, Issue:7

    Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans

2017
Response to "Baclofen and alcohol use disorders: From miracle to mirage".
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2017, Volume: 27, Issue:7

    Topics: Alcohol-Related Disorders; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans

2017
    Revue medicale suisse, 2016, Sep-14, Volume: 12, Issue:530

    Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Treatment Outcome

2016
Severity of Baclofen Self-Poisoning Linked to Psychiatric Co-morbidity in Alcohol-Dependent Patients: Better Measurement of Risk and Benefit.
    Basic & clinical pharmacology & toxicology, 2017, Volume: 121, Issue:4

    Topics: Alcoholism; Baclofen; Comorbidity; Ethanol; Humans; Risk

2017
    Revue medicale suisse, 2016, Nov-16, Volume: 12, Issue:539

    Topics: Alcoholism; Baclofen; Electronic Nicotine Delivery Systems; France; Humans

2016
    Revue medicale suisse, 2017, Mar-29, Volume: 13, Issue:556

    Topics: Alcoholism; Baclofen; Food Labeling; France; Health Services Accessibility; Humans

2017
One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:10

    Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Female; France; GABA-B Receptor A

2017
Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons.
    Drug and alcohol dependence, 2017, 10-01, Volume: 179

    Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Baclofen; Disease Models, Animal; GABA-B

2017
A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic.
    Alcohol (Fayetteville, N.Y.), 2017, Volume: 62

    Topics: Adult; Aged; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Bilirubin; Biomarkers; Coho

2017
Baclofen and the "first do not harm" motto: a new French paradox?
    Clinical toxicology (Philadelphia, Pa.), 2018, Volume: 56, Issue:4

    Topics: Alcoholism; Baclofen; Ethanol; Humans; Poison Control Centers

2018
Focusing solely on the effect of the medication without taking a holistic view of the patient does not seem very constructive.
    Clinical toxicology (Philadelphia, Pa.), 2018, Volume: 56, Issue:4

    Topics: Alcoholism; Baclofen; Ethanol; Humans; Language; Poison Control Centers

2018
LC-MS/MS method for quantification of baclofen in hair: A useful tool to assess compliance in alcohol dependent patients?
    Drug testing and analysis, 2018, Volume: 10, Issue:4

    Topics: Alcoholism; Baclofen; Biomarkers; Chromatography, Liquid; Drug Monitoring; Ethanol; Female; GABA-B R

2018
Baclofen Self-Poisoning in the Era of Changing Indication: Multicentric Reports to a French Poison Control Centre.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2017, Nov-01, Volume: 52, Issue:6

    Topics: Adult; Alcoholism; Baclofen; Drug Overdose; Female; France; Humans; Male; Middle Aged; Muscle Relaxa

2017
On-the-ground application of the 'temporary recommendation for use' regulatory measure on off-label use of baclofen for alcohol dependence in France: a regional survey of community pharmacies.
    Fundamental & clinical pharmacology, 2018, Volume: 32, Issue:2

    Topics: Alcoholism; Attitude of Health Personnel; Baclofen; Community Pharmacy Services; Drug and Narcotic C

2018
Response to the Letter to the Editor Regarding "Baclofen and Alcohol-Dependent Patients: A Real Risk of Severe Self-Poisoning."
    Basic & clinical pharmacology & toxicology, 2018, Volume: 122, Issue:1

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Ethanol; Humans; Risk

2018
An observational study of benzodiazepine prescription during inpatient alcohol detoxification for patients with vs. without chronic pretreatment with high-dosage baclofen.
    Fundamental & clinical pharmacology, 2018, Volume: 32, Issue:2

    Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Baclofen; Diazepam; Female; GABA Modulato

2018
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?
    Addiction (Abingdon, England), 2018, Volume: 113, Issue:2

    Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Netwo

2018
Baclofen and sleep apnoea syndrome: analysis of VigiBase, the WHO pharmacovigilance database.
    The European respiratory journal, 2018, Volume: 51, Issue:1

    Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Alcoholism; Apnea; Baclofen; Database

2018
The need for patient-tailored dosing of baclofen in future clinical trials
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2018, Volume: 28, Issue:5

    Topics: Alcoholism; Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central

2018
Functional inactivation of the orbitofrontal cortex disrupts context-induced reinstatement of alcohol seeking in rats.
    Drug and alcohol dependence, 2018, 05-01, Volume: 186

    Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Conditioning, Operant; Drug-Seeking Behavior; Femal

2018
An observational study of benzodiazepine prescription during inpatient alcohol detoxification for patients with versus without chronic pretreatment with high dosage baclofen.
    Fundamental & clinical pharmacology, 2018, Volume: 32, Issue:2

    Topics: Alcoholism; Baclofen; Benzodiazepines; Dose-Response Relationship, Drug; Humans; Inpatients

2018
Efficacy and side effects of baclofen and the novel GABA
    Psychopharmacology, 2018, Volume: 235, Issue:7

    Topics: Alcoholism; Allosteric Regulation; Animals; Baclofen; Behavior, Addictive; Cocaine; Cocaine-Related

2018
Moderation of baclofen response by a GABA
    Addiction (Abingdon, England), 2018, Volume: 113, Issue:12

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Female; GABA-B Receptor Agonists; Humans; Male; Middl

2018
Delirium tremens in an AUD patient after an intrathecal baclofen pump induced total alcohol abstinence.
    European review for medical and pharmacological sciences, 2018, Volume: 22, Issue:16

    Topics: Alcohol Abstinence; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Baclofen; Diazepam; H

2018
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
    Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:11

    Topics: Acamprosate; Administrative Claims, Healthcare; Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofe

2018
Baclofen and alcohol in France.
    The lancet. Psychiatry, 2018, Volume: 5, Issue:12

    Topics: Alcoholism; Baclofen; Ethanol; France; Humans

2018
Baclofen and alcohol in France - Authors' reply.
    The lancet. Psychiatry, 2018, Volume: 5, Issue:12

    Topics: Alcoholism; Baclofen; Ethanol; France; Humans

2018
Baclofen for the treatment of alcohol use disorder: the Cagliari Statement.
    The lancet. Psychiatry, 2018, Volume: 5, Issue:12

    Topics: Alcoholism; Baclofen; Humans

2018
Letter to the Editor: No Baclofen for Alcohol Use Disorders Even More When Liver Disease Is Serious!
    Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:6

    Topics: Alcoholism; Baclofen; End Stage Liver Disease; Humans; Liver Diseases, Alcoholic

2019
A capture-recapture method for estimating the incidence of off-label prescriptions: the example of baclofen for alcohol use disorder in France.
    Therapie, 2019, Volume: 74, Issue:6

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Alcoholism; Baclofen; Data Mining; Databases,

2019
Baclofen for alcohol-dependence: anticraving or partial substitution?
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2

    Topics: Alcoholism; Baclofen; Female; GABA-B Receptor Agonists; Humans; Male

2013
Reply to Dr Rolland et al re: "Baclofen for alcohol-dependence: anticraving or partial substitution?".
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2

    Topics: Alcoholism; Baclofen; Female; GABA-B Receptor Agonists; Humans; Male

2013
Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center.
    Alcoholism, clinical and experimental research, 2013, Volume: 37, Issue:9

    Topics: Adult; Aged; Alcohol Abstinence; Alcoholics; Alcoholism; Baclofen; Female; Follow-Up Studies; Humans

2013
[Alcoholism and baclofen: a strange French affair].
    Revue medicale suisse, 2013, Jun-12, Volume: 9, Issue:390

    Topics: Alcoholism; Baclofen; Ethanol; France; Humans

2013
[The death of Dr. Olivier Ameisen, promoter of baclofen for alcoholism].
    Revue medicale suisse, 2013, Aug-28, Volume: 9, Issue:395

    Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Physicians; Self Medication

2013
High variability in the exposure of baclofen in alcohol-dependent patients.
    Alcoholism, clinical and experimental research, 2014, Volume: 38, Issue:2

    Topics: Adult; Aged; Alcoholism; Algorithms; Area Under Curve; Baclofen; Dose-Response Relationship, Drug; F

2014
Severity of deliberate acute baclofen poisoning: a nonconcurrent cohort study.
    Basic & clinical pharmacology & toxicology, 2014, Volume: 114, Issue:4

    Topics: Adult; Alcoholism; Baclofen; Dose-Response Relationship, Drug; Drug Overdose; Endpoint Determination

2014
Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns--a cohort study.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:2

    Topics: Alcoholism; Baclofen; Dantrolene; Europe; Female; France; Hospitalization; Humans; Incidence; Male;

2014
Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder.
    Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Baclofen; Conf

2014
[Involvement of pharmacists in systems for supervising off-label medications: example of the CAMTEA system for the prescription of baclofen in alcohol use disorder in Northern France].
    Annales pharmaceutiques francaises, 2014, Volume: 72, Issue:1

    Topics: Alcoholism; Baclofen; Directive Counseling; Feasibility Studies; France; Humans; Off-Label Use; Pati

2014
Severe tinnitus induced by off-label baclofen.
    The Annals of pharmacotherapy, 2014, Volume: 48, Issue:5

    Topics: Alcoholism; Baclofen; Dose-Response Relationship, Drug; Female; GABA-B Receptor Agonists; Humans; Ma

2014
[Alcohol and baclofen: France will finally experiment on a large scale].
    Revue medicale suisse, 2014, Mar-26, Volume: 10, Issue:423

    Topics: Alcoholic Beverages; Alcoholism; Baclofen; Dose-Response Relationship, Drug; France; Humans; Muscle

2014
Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Alcoholism; Baclofen; Data Collection; Dose-Response Relationship, Drug; Drug Prescriptions; France;

2014
[Addictions, alcoholism and baclofen: latest French news].
    Revue medicale suisse, 2014, Jun-18, Volume: 10, Issue:435

    Topics: Alcoholism; Baclofen; France; Humans; Off-Label Use; Practice Patterns, Physicians'; Reimbursement M

2014
[Baclofen: Innovative treatment or French controversy?].
    La Revue de medecine interne, 2015, Volume: 36, Issue:1

    Topics: Alcoholism; Baclofen; Behavior; Dissent and Disputes; Drug Repositioning; France; History, 21st Cent

2015
Death of an alcohol-dependent patient following intentional drug intoxication: implication of baclofen?
    European addiction research, 2014, Volume: 20, Issue:6

    Topics: Alcoholism; Antipruritics; Baclofen; Central Nervous System Depressants; Drug Overdose; Ethanol; Fat

2014
Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study.
    International clinical psychopharmacology, 2015, Volume: 30, Issue:1

    Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Borderline Personality Disorder;

2015
Increase of baclofen intoxications: risks involved and management.
    The Netherlands journal of medicine, 2014, Volume: 72, Issue:9

    Topics: Alcoholism; Baclofen; Diagnosis, Dual (Psychiatry); Female; GABA-B Receptor Agonists; Humans; Middle

2014
Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption.
    Alcohol (Fayetteville, N.Y.), 2015, Volume: 49, Issue:1

    Topics: Alcoholism; Animals; Baclofen; Binge Drinking; Disease Models, Animal; Dose-Response Relationship, D

2015
[Baclofen: don't forget the initial therapeutic indications].
    Presse medicale (Paris, France : 1983), 2015, Volume: 44, Issue:4 Pt 1

    Topics: Aged; Alcoholism; Arthralgia; Baclofen; Humans; Male; Substance Withdrawal Syndrome

2015
Attitudes of community pharmacists to off-label prescribing of baclofen in Northern France.
    International journal of clinical pharmacy, 2015, Volume: 37, Issue:2

    Topics: Alcoholism; Attitude of Health Personnel; Baclofen; Community Pharmacy Services; France; GABA-B Rece

2015
[Addiction].
    Revue medicale suisse, 2015, Jan-14, Volume: 11, Issue:456-457

    Topics: Alcoholism; Baclofen; Cell Phone; Empathy; GABA-B Receptor Agonists; Humans; Substance-Related Disor

2015
High-dose baclofen: withdrawal syndrome following abrupt discontinuation.
    Prescrire international, 2014, Volume: 23, Issue:153

    Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Drug Administration Schedule; GABA-B Rec

2014
Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy.
    Current drug targets, 2016, Volume: 17, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholics; Alcoholism; Baclofen; Carcinoma, Hepatocellular; Drug C

2016
Tolerability of High-dose Baclofen in the Treatment of Patients with Alcohol Disorders: A Retrospective Study.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2015, Volume: 50, Issue:5

    Topics: Adult; Alcoholism; Baclofen; Depression; Dose-Response Relationship, Drug; Female; GABA-B Receptor A

2015
Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2015, Volume: 25, Issue:10

    Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Central Nervous System Depressants; Dose

2015
Anticraving Effect of Baclofen in Alcohol-Dependent Patients.
    Alcoholism, clinical and experimental research, 2015, Volume: 39, Issue:9

    Topics: Adult; Aged; Alcoholism; Baclofen; Craving; Female; GABA-B Receptor Agonists; Humans; Male; Middle A

2015
High doses of Baclofen as suicide attempt in patients with alcohol use disorders - A serious concern.
    Asian journal of psychiatry, 2015, Volume: 17

    Topics: Adult; Alcoholism; Baclofen; Drug Overdose; Humans; Male; Muscle Relaxants, Central; Suicide, Attemp

2015
Baclofen-Associated Onset of Central Sleep Apnea in Alcohol Use Disorder: A Case Report.
    Respiration; international review of thoracic diseases, 2015, Volume: 90, Issue:6

    Topics: Alcoholism; Baclofen; Continuous Positive Airway Pressure; GABA-B Receptor Agonists; Humans; Male; M

2015
Efficacy of High-Dose Baclofen for Alcohol Use Disorder and Comorbid Bulimia: A Case Report.
    Journal of dual diagnosis, 2015, Volume: 11, Issue:3-4

    Topics: Adult; Alcoholism; Baclofen; Bulimia Nervosa; Craving; Diagnosis, Dual (Psychiatry); Female; Humans;

2015
[Baclofen: when does one know the scientific truth about its effectiveness in alcoholic disease?].
    Revue medicale suisse, 2015, Sep-09, Volume: 11, Issue:485

    Topics: Alcohol Deterrents; Alcoholism; Baclofen; Evidence-Based Medicine; GABA-B Receptor Agonists; Humans;

2015
Characteristics of Patients with Alcohol Dependence Seeking Baclofen Treatment in France: A Two-Centre Comparative Cohort Study.
    Alcohol and alcoholism (Oxford, Oxfordshire), 2016, Volume: 51, Issue:6

    Topics: Alcoholism; Baclofen; Female; France; GABA-B Receptor Agonists; Humans; Male; Middle Aged; Patient A

2016
Severe Central Sleep Apnea Associated With Chronic Baclofen Therapy: A Case Series.
    Chest, 2016, Volume: 149, Issue:5

    Topics: Aged; Alcoholism; Baclofen; Central Nervous System Depressants; Ethanol; Humans; Male; Middle Aged;

2016
[The baclofene saga and the paradigm shift in alcohol addiction treatment].
    Presse medicale (Paris, France : 1983), 2016, Volume: 45, Issue:12 Pt 1

    Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Practice Guidelines as Topic; Treatment Outc

2016
[Manic symptoms induced by high doses of baclofen: A case report].
    L'Encephale, 2016, Volume: 42, Issue:4

    Topics: Adult; Alcoholism; Antimanic Agents; Baclofen; Bipolar Disorder; Bromazepam; GABA Agonists; Humans;

2016
BACLOFEN-INDUCED PSYCHOSIS IN A PATIENT WITH ALCOHOL DEPENDENCE.
    Turk psikiyatri dergisi = Turkish journal of psychiatry, 2015,Winter, Volume: 26, Issue:4

    Topics: Adult; Alcohol Deterrents; Alcoholism; Baclofen; Diagnosis, Differential; GABA-B Receptor Agonists;

2015
[Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms].
    Nederlands tijdschrift voor geneeskunde, 2016, Volume: 160

    Topics: Adult; Aggression; Alcoholism; Baclofen; Delirium; Drug Overdose; GABA-B Receptor Agonists; Humans;

2016
Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol.
    Expert opinion on drug safety, 2017, Volume: 16, Issue:2

    Topics: Alcohol Drinking; Alcoholism; Algorithms; Baclofen; Cohort Studies; Drug Monitoring; Follow-Up Studi

2017
Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France.
    Drug safety, 2017, Volume: 40, Issue:3

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alcoholism; Bac

2017
Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008-2013.
    Clinical toxicology (Philadelphia, Pa.), 2017, Volume: 55, Issue:4

    Topics: Adolescent; Adult; Aged; Alcoholism; Baclofen; Cause of Death; Dose-Response Relationship, Drug; Dru

2017
Comment on: "Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France".
    Drug safety, 2017, Volume: 40, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Alcoholism; Baclofen; France; Humans; Off-Label Use; Pharma

2017
Authors' Reply to Alain Braillon's Comment on "Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in F
    Drug safety, 2017, Volume: 40, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Alcoholism; Baclofen; France; Humans; Off-Label Use; Pharma

2017
Baclofen-Related Mania: Lower Threshold for Bipolar Patients?
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:2

    Topics: Alcoholism; Baclofen; Bipolar Disorder; GABA-A Receptor Agonists; Humans; Male; Middle Aged

2017
Specific reduction of alcohol's motivational properties by the positive allosteric modulator of the GABAB receptor, GS39783--comparison with the effect of the GABAB receptor direct agonist, baclofen.
    Alcoholism, clinical and experimental research, 2008, Volume: 32, Issue:9

    Topics: Alcoholism; Animals; Baclofen; Behavior, Animal; Central Nervous System Depressants; Cyclopentanes;

2008
Relationship between the hypothalamic-pituitary-thyroid axis and alcohol craving in alcohol-dependent patients: a longitudinal study.
    Alcoholism, clinical and experimental research, 2008, Volume: 32, Issue:12

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Behavior, Addictive; Female; Humans; Hypothalamo-Hypo

2008
[Alcoholism: history is not finished...].
    Revue medicale suisse, 2008, Sep-03, Volume: 4, Issue:169

    Topics: Alcoholism; Animals; Baclofen; Disease Models, Animal; Follow-Up Studies; GABA Agonists; Neurokinin-

2008
[Suppression of alcoholism with baclofen: a physician's personal story].
    Revue medicale suisse, 2008, Oct-15, Volume: 4, Issue:175

    Topics: Alcoholism; Baclofen; GABA Agonists; Humans; Male; Middle Aged; Physician Impairment; Self Care; Sel

2008
Complete suppression of craving in alcohol-dependent individuals: is it possible?
    CNS drugs, 2009, Volume: 23, Issue:5

    Topics: Alcohol Deterrents; Alcoholism; Baclofen; Behavior, Addictive; Clinical Trials as Topic; Humans

2009
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
    Prescrire international, 2009, Volume: 18, Issue:103

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism

2009
Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives.
    Alcohol (Fayetteville, N.Y.), 2009, Volume: 43, Issue:7

    Topics: Alcoholism; Animals; Baclofen; GABA-B Receptor Agonists; Humans; Receptors, GABA-B; Stress, Psycholo

2009
Behavioral disinhibition with baclofen.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:6

    Topics: Aged; Alcoholism; Baclofen; Behavioral Symptoms; GABA-B Receptor Agonists; Humans; Inhibition, Psych

2010
Baclofen-induced morbiliform rashes: a case series.
    Journal of clinical pharmacology, 2011, Volume: 51, Issue:12

    Topics: Adult; Alcoholism; Baclofen; Exanthema; Female; GABA-B Receptor Agonists; Humans; Male

2011
High-dose baclofen for suppression of alcohol dependence.
    Alcoholism, clinical and experimental research, 2011, Volume: 35, Issue:5

    Topics: Alcoholism; Baclofen; Female; GABA Agonists; Humans; Male

2011
Baclofen effect related to liver damage.
    Alcoholism, clinical and experimental research, 2011, Volume: 35, Issue:5

    Topics: Alcoholism; Baclofen; Female; GABA Agonists; Humans; Male

2011
Addiction research. Anonymous alcoholic bankrolls trial of controversial therapy.
    Science (New York, N.Y.), 2011, May-06, Volume: 332, Issue:6030

    Topics: Alcoholism; Baclofen; Controlled Clinical Trials as Topic; Financial Support; GABA-B Receptor Agonis

2011
Baclofen-induced acute hepatitis in alcohol-dependent patient.
    Clinics and research in hepatology and gastroenterology, 2011, Volume: 35, Issue:5

    Topics: Acute Disease; Alcoholism; Baclofen; Chemical and Drug Induced Liver Injury; Female; GABA-B Receptor

2011
[Baclofen for alcohol addiction].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011, Nov-01, Volume: 131, Issue:21

    Topics: Alcoholism; Baclofen; Evidence-Based Medicine; GABA-B Receptor Agonists; Humans; Muscle Relaxants, C

2011
[Baclofen will also have to be compared with approved medications of alcohol dependence].
    Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:2

    Topics: Alcoholism; Baclofen; Drug Approval; Humans

2012
[Misuse of alcohol and new drug treatments].
    La Revue du praticien, 2011, Volume: 61, Issue:10

    Topics: Alcoholism; Antipsychotic Agents; Aripiprazole; Baclofen; GABA-B Receptor Agonists; Humans; Ondanset

2011
Alcohol-dependence: the current French craze for baclofen.
    Addiction (Abingdon, England), 2012, Volume: 107, Issue:4

    Topics: Alcoholism; Baclofen; France; GABA Agonists; Humans

2012
High-dose baclofen for treatment-resistant alcohol dependence.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:2

    Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Dose-Response Relationship, Drug; Female; GABA-B Rece

2012
Levetiracetam in the treatment of alcohol dependence: toward the end of the story?
    Alcoholism, clinical and experimental research, 2012, Volume: 36, Issue:8

    Topics: Alcoholism; Anticonvulsants; Baclofen; Double-Blind Method; GABA Agonists; Humans; Levetiracetam; Pi

2012
Baclofen for the treatment of alcohol dependence.
    Journal of psychosocial nursing and mental health services, 2012, Volume: 50, Issue:10

    Topics: Alcoholism; Baclofen; Clinical Trials as Topic; GABA-B Receptor Agonists; Humans

2012
Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice.
    Addiction biology, 2013, Volume: 18, Issue:1

    Topics: Adolescent; Alcohol Drinking; Alcoholism; Analysis of Variance; Animals; Baclofen; Disease Models, A

2013
Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats.
    Drug and alcohol dependence, 2003, May-01, Volume: 70, Issue:1

    Topics: Alcoholism; Animals; Baclofen; Central Nervous System Depressants; Disease Models, Animal; Ethanol;

2003
Rats on the grog: novel pharmacotherapies for alcohol craving.
    Addictive behaviors, 2004, Volume: 29, Issue:7

    Topics: Alcoholism; Animals; Baclofen; Beer; Behavior, Addictive; Cannabinoid Receptor Antagonists; Corticot

2004
Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:5

    Topics: Alcoholism; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Baclofen; Bipolar Disord

2004
Tolerance to baclofen's sedative effect in alcohol-addicted patients: no dissipation after a period of abstinence.
    Psychopharmacology, 2005, Volume: 178, Issue:2-3

    Topics: Alcohol Withdrawal Delirium; Alcoholism; Baclofen; Drug Interactions; Drug Tolerance; Ethanol; Human

2005
Naltrexone treatment for alcohol dependency.
    JAMA, 2005, Aug-24, Volume: 294, Issue:8

    Topics: Administration, Oral; Alcoholism; Animals; Baclofen; Ethanol; GABA Agonists; Humans; Naltrexone; Nar

2005
The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats.
    Alcoholism, clinical and experimental research, 2007, Volume: 31, Issue:1

    Topics: Alcoholism; Animals; Baclofen; Central Nervous System Depressants; Conditioning, Operant; Data Inter

2007
Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:3

    Topics: Alcohol Drinking; Alcoholism; Baclofen; Behavior, Addictive; GABA Agonists; Humans; Male; Middle Age

2007
GABAergic modulation of binge-like ethanol intake in C57BL/6J mice.
    Pharmacology, biochemistry, and behavior, 2007, Volume: 88, Issue:1

    Topics: Alcoholism; Animals; Baclofen; Central Nervous System Depressants; Darkness; Dose-Response Relations

2007
GABAergic medications for treating alcohol dependence.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5

    Topics: Alcoholism; Baclofen; Drug Therapy, Combination; GABA Agonists; gamma-Aminobutyric Acid; Humans; Hyd

2007
Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review.
    The Journal of the Oklahoma State Medical Association, 2007, Volume: 100, Issue:9

    Topics: Alcoholism; Baclofen; Humans; Retrospective Studies; Substance Withdrawal Syndrome

2007
Growth hormone response to the GABA-B agonist baclofen in 3-week abstinent alcoholics.
    Alcohol (Fayetteville, N.Y.), 2007, Volume: 41, Issue:8

    Topics: Administration, Oral; Adult; Alcoholism; Baclofen; Case-Control Studies; GABA Agonists; GABA-B Recep

2007
Are the effects of gamma-hydroxybutyrate (GHB) treatment partly physiological in alcohol dependence?
    The American journal of drug and alcohol abuse, 2008, Volume: 34, Issue:2

    Topics: Alcoholism; Baclofen; GABA Agonists; GABA-B Receptor Agonists; Humans; Sodium Oxybate

2008
Baclofen reduces ethanol intake in high-alcohol-drinking University of Chile bibulous rats.
    Addiction biology, 2008, Volume: 13, Issue:3-4

    Topics: Alcoholism; Animals; Baclofen; Behavior, Animal; Choice Behavior; Disease Models, Animal; Ethanol; L

2008
The effects of ethanol, phenobarbital, and baclofen on ethanol withdrawal in the rhesus monkey.
    Psychopharmacology, 1980, Volume: 70, Issue:2

    Topics: Alcoholism; Animals; Ataxia; Baclofen; Behavior, Animal; Drug Interactions; Ethanol; Humans; Macaca

1980
Alcoholism abolishes the gamma-aminobutyric acid (GABA)ergic control of GH secretion in humans.
    Alcohol (Fayetteville, N.Y.), 1998, Volume: 16, Issue:4

    Topics: Adult; Alcoholism; Baclofen; GABA Agents; GABA Agonists; gamma-Aminobutyric Acid; Human Growth Hormo

1998
Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.
    Alcoholism, clinical and experimental research, 2000, Volume: 24, Issue:1

    Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Dose-Response Relationship, Drug; Drug Evaluation,

2000
Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence.
    Alcoholism, clinical and experimental research, 2000, Volume: 24, Issue:1

    Topics: Adult; Alcohol Drinking; Alcoholism; Animals; Baclofen; Combined Modality Therapy; Dose-Response Rel

2000
Different control of GH secretion by gamma-amino- and gamma-hydroxy-butyric acid in 4-year abstinent alcoholics.
    Drug and alcohol dependence, 2001, Feb-01, Volume: 61, Issue:3

    Topics: Adult; Alcoholism; Baclofen; Biomarkers; GABA Agents; GABA Agonists; gamma-Aminobutyric Acid; Growth

2001